How Weight-Loss Drugs Could Impact U.S. Healthcare and Food. Plus, the Biggest Problems With GLP1s.

How Weight-Loss Drugs Could Impact U.S. Healthcare and Food. Plus, the Biggest Problems With GLP1s.

Today’s episode is our second in a series on the weight-loss drug revolution of the last two years. On Tuesday, we talked to endocrinologist Beverly Tchang about the science of glucagon like peptide 1 receptor agonists—also known as GLP1s, also known as Ozempic, Wegovy, Moujargo, and Zepbound. If you haven’t listened to that show, I think you’ll feel safe and entertained within the bounds of this episode. But if you want to know more about how these drugs work, their effect on insulin and glucose and the brain’s reward center, or the questions they raise about obesity and the nature of willpower and free will, I’d encourage you to queue up that show. Today, in Part 2, we have two guests: Zach Reitano is the CEO and cofounder of the telehealth platform Ro. He is here for a couple reasons. He has a bird’s-eye view of the GLP1 marketplace, the rise in demand, the supply chain, the economics of pricing and insurance. He’s also written several revelatory essays, pulling in research from think tanks, medical experts, and investment banks, that have helped shape my understanding of these drugs and the effect they could have on the population and the economy. Our second guest is Dr. Robert Lustig, an endocrinologist who spent years as a pediatrician and researcher at the University of California-San Francisco. As you’ll hear, he is much less optimistic about the ability of these drugs to revolutionize obesity medication in America. If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guests: Zach Reitano & Robert Lustig Producer: Devon Baroldi Learn more about your ad choices. Visit podcastchoices.com/adchoices

Episoder(360)

This Is How the AI Bubble Could Burst

This Is How the AI Bubble Could Burst

This year, American tech companies will spend $300 billion to $400 billion on artificial intelligence, which is in nominal dollars more than any group of companies have ever spent to do anything. Nota...

23 Sep 202559min

The Jimmy Kimmel Saga and America's Free-Speech Crisis

The Jimmy Kimmel Saga and America's Free-Speech Crisis

Matt Belloni, the host of the Town podcast and the author of Puck’s 'What I’m Hearing' newsletter, joins the show to talk about Jimmy Kimmel's punishment, what happened behind the scenes at ABC and Di...

19 Sep 202540min

If GLP-1 Drugs Are Good for Everything, Should We All Be on Them?

If GLP-1 Drugs Are Good for Everything, Should We All Be on Them?

To read more of Derek's reporting on GLP-1 drugs, you can subscribe to his Substack here. GLP-1 drugs like Ozempic and Zepbound don't just help with Type 2 diabetes and weight loss. They seem to curb...

16 Sep 202554min

Charlie Kirk's Killing and America's Age of "Salad-Bar Extremism"

Charlie Kirk's Killing and America's Age of "Salad-Bar Extremism"

In the past few years, we have witnessed a frightening spiral of political violence. We’ve seen the killing of Charlie Kirk; the killing of Brian Thompson, the health insurance executive; the assassin...

12 Sep 202552min

America in the Age of Diagnosis

America in the Age of Diagnosis

America is sicker than ever. That’s what the data says, anyway. Psychological and psychiatric diagnoses have soared. Between the 1990s and the mid-2000s, bipolar disorder among American youth grew by...

9 Sep 202557min

Trumponomics Explained, Part 2: The Enshittification of American Power

Trumponomics Explained, Part 2: The Enshittification of American Power

In the second of our two-episode series on Donald Trump, economics, and power, we talk to Henry Farrell, a professor of political science at Johns Hopkins. Farrell has written extensively on how the U...

5 Sep 202552min

What Is Trumponomics? Part 1: How Donald Trump Is Breaking American Capitalism

What Is Trumponomics? Part 1: How Donald Trump Is Breaking American Capitalism

Today is the first of two interviews this week trying to answer this question: What is Trumponomics? From the 1980s to the 2010s, it was generally assumed that Republicans and Democrats had settled d...

3 Sep 202549min

The Healthiest "Super-Agers" Have One Thing in Common, According to a 25-Year Study

The Healthiest "Super-Agers" Have One Thing in Common, According to a 25-Year Study

Memory is the glue of life. Without it, our focus softens, our experience of the world blurs, and our identities melt away. But as people age, their memory declines. Many billions of dollars have been...

27 Aug 202541min

Populært innen Politikk og nyheter

giver-og-gjengen-vg
aftenpodden
aftenpodden-usa
forklart
stopp-verden
i-retten
popradet
lydartikler-fra-aftenposten
rss-gukild-johaug
det-store-bildet
nokon-ma-ga
dine-penger-pengeradet
fotballpodden-2
rss-ness
hanna-de-heldige
aftenbla-bla
frokostshowet-pa-p5
rss-dannet-uten-piano
rss-utenrikskomiteen-med-bogen-og-grasvik
ta-dokumentar